Advertisement

European Journal of Clinical Pharmacology

, Volume 40, Issue 1, pp 101–106 | Cite as

Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states

  • I. W. Taylor
  • T. Taylor
  • I. James
  • G. Doyle
  • G. Dorf
  • A. Darragh
  • L. F. Chasseaud
Originals

Summary

The pharmacokinetics of ximoprofen, a potent new non-steroidal anti-inflammatory agent, has been investigated in normal healthy subjects and in patients with hepatic or renal disease.

After intravenous infusion of 22.8 mg to healthy subjects, plasma ximoprofen concentrations declined in a polyexponential manner with a terminal phase half-life of 1.9 h. The systemic clearance of ximoprofen was 115 ml·min−1 and the volumes of distribution were 18.0 l Vz and 13.8 l Vss. Ximoprofen was 80–90% bound to plasma proteins. The systemic availabilities (f) of orally and rectally administered doses of 30 mg of ximoprofen were 98% and 56% respectively and, in the case of the rectal dose, absorption appeared to be prolonged leading to “flip-flop” kinetics.

After single oral doses of 30 mg of ximoprofen to patients with hepatic disease, half-life (2.2 h), peak plasma concentrations (1.55 μg·ml−1 cf 1.04 μg·ml−1 in healthy subjects) and areas under the curve (6.12 μg·h·ml−1 cf 3.54 μg·h·ml−1 in healthy subjects) were significantly different from those in healthy subjects.

After single oral doses of 30 mg of ximoprofen to patients with renal disease, pharmacokinetic parameters of half-life (4.0 h), mean residence time (6.0 h) and area under the curve (9.2 μg·h·ml−1) were significantly different from those in healthy subjects. There were no significant differences in pharmacokinetic parameters between patients having differing degrees of renal disease.

These data nevertheless suggest that accumulation of ximoprofen in hepatic or renal disease would be of slight or negligible clinical relevance and that no alteration of the dose regimen (up to 15 mg twice daily) may be required when ximoprofen is administered in these disease states.

Key words

Ximoprofen pharmacokinetics normal subjects hepatic disease renal disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams SS (1987) Non-steroidal anti-inflammatory drugs, plasma half-lives and adverse reactions. Lancet II: 1204–1205Google Scholar
  2. Bass NM, Williams RL (1988) Guide to drug dosage in hepatic disease. Clin Pharmacokinet 15: 396–420Google Scholar
  3. Bennett WM (1988) Guide to drug dosage in renal failure. Clin Pharmacokinet 15: 326–354Google Scholar
  4. Caporal R, Cottin S, Dreyfus P, Guidet M, Jauffret P, Schoen E, Laffez B (1987) Ximoprofen and inflammatory rheumatoid disease. Clin Exp Rheumatol 5 [Suppl 2] Abstr P 405Google Scholar
  5. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6: 539–546Google Scholar
  6. Cutler DJ (1979) A linear recirculation model for drug disposition. J Pharmacokinet Biopharm 7: 101–116Google Scholar
  7. Davies O (1961) Linear relationships between two variables. Statistical Methods in Research and Production, 3rd Ed, Oliver and Boyd, London, pp 150–207Google Scholar
  8. Flower RJ, Moncada S, Vane JR (1985) Analgesic antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman AG, Gilman LS, Rall T, Murad F (eds) The Pharmacological Basis of Therapeutics. 7th edn, Macmillan, New York, pp 674–715Google Scholar
  9. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd Edn. Dekker, New YorkGoogle Scholar
  10. Langenbucher F (1982) Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind 44: 1166–1171Google Scholar
  11. Lin JH, Cocchetto DM, Duggan DE (1987) Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12: 402–432Google Scholar
  12. Maillard J, Langlois M, Delaunay P, VoVan T, Meingan JP, Rapin M, Morin R, Manuel C, Mazmanian C (1977) Anti-inflammatoires derives de l'acide phenylacetique. 111. Derives oxygenes de l'acide cyclohexyl-4 phenylacetique. Eur J Med Chem Chim Ther 12: 161–171Google Scholar
  13. Mayo BC, Chasseaud LF, Hawkins DR, Taylor IW, Legeai J (1990) The metabolic fate of 14C-ximoprofen in rats, baboons and humans. Xenobiotica 20: 233–246Google Scholar
  14. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646–649Google Scholar
  15. Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509–534Google Scholar
  16. Slater JDH (1969) In: Clinical Physiology, Campbell EJM, Dickinson CJ, Slater JDH (eds) Blackwell, OxfordGoogle Scholar
  17. Taylor IW, Chasseaud LF (1989) Determination of ximoprofen in human plasma by gas chromatography. J Chromatogr 495: 275–280Google Scholar
  18. Wagner JG (1983) Significance of ratios of different volumes of distribution in pharmacokinetics. Biopharm Drug Dispos 4: 263–270Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • I. W. Taylor
    • 1
  • T. Taylor
    • 1
  • I. James
    • 2
  • G. Doyle
    • 3
  • G. Dorf
    • 4
  • A. Darragh
    • 5
  • L. F. Chasseaud
    • 1
  1. 1.Department of Metabolism and PharmacokineticsHuntingdon Research Centre LtdHuntingdonUK
  2. 2.Royal Free HospitalHampstead LondonUK
  3. 3.Beaumont HospitalDublinIreland
  4. 4.Clinique ThérapeutiqueHôpital LariboisièreParisFrance
  5. 5.Institute of Clinical PharmacologySir Patrick Dun's HospitalDublinIreland

Personalised recommendations